Integrating BRAF/MEK inhibitors into combination therapy for melanoma

The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, K S M, Flaherty, K T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658537/
https://www.ncbi.nlm.nih.gov/pubmed/19156138
http://dx.doi.org/10.1038/sj.bjc.6604891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658537/
https://www.ncbi.nlm.nih.gov/pubmed/19156138
http://dx.doi.org/10.1038/sj.bjc.6604891

Ejemplares similares